2011

Let's look 'under the hoods' of two pharma-sponsored mobile apps and compare disclaimers. We'll compare Janssen's PASI calculator, which has an update disclaimer, with the new AFib Educator 2.0 app developed by Sanofi-Aventis.

How much money the pharmaceutical industry spends on Internet marketing, direct-to-consumer advertising, and physician detailing are always topics of interest and 2010 was no exception. 2010 was, however, a turning point in bringing more attention to payments made to physicians for speaking, consulting, and research.

According to a Bad Ad Program 2010-2011 Year End Report just issued by the FDA, the program is a success despite the fact that ONLY 125 complaints were deemed worthy of

From the Audition in the Press to TV, Web, and Print Advertising. Pfizer and Amgen demonstrate how to launch a branded spokesperson campaign starting from a bit of over-the-top unregulated press relations to fully regulated TV, print, and Web advertising. It must be costing a mint!

The long-awaited social media guidance from the FDA -- whenever it arrives -- may turn out to be nothing more than a stamp of approval on activities in which the industry is currently engaged. Practically every issue that FDA guidance is expected to address has already been handled independently by a few pioneering pharmaceutical companies. Rather than waiting for FDA's anti climatic guidelines, Pharmaguy decided to publish The Pharmaguy Social Media Timeline™ now, at a time when the industry already has set precedents in every social media application.

All pharma companies face a communications crisis that rests on the changing role of the medical sales representative. This evolution has a direct impact on the obligations of the pharma marketing organizations to be both proactive and responsive in helping to protect their organizations from the threat of non-compliance. What can marketing do? This article offers a few thoughts from a physician's point.

Welcome to Volume 10, Issue #19 (21 DECEMBER 2011) of Pharma Marketing News.

The long-awaited social media guidance from the FDA -- whenever it arrives -- may turn out to be nothing more than a stamp of approval on activities in which the industry is currently engaged. Practically every issue that FDA guidance is expected to address has already been handled independently by a few pioneering pharmaceutical companies. Rather than waiting for FDA's anti climatic guidelines, Pharmaguy decided to publish The Pharmaguy Social Media Timeline™ now, at a time when the industry already has set precedents in every social media application.

This article summaries research data exploring why physicians interested in using online peer-to-peer social communities outnumber by 2 to 1 physicians who are actually using them. Includes suggestions for what these communities must do in order to provide more value to physicians.

The long-awaited social media guidance from the FDA -- whenever it arrives -- may turn out to be nothing more than a stamp of approval on activities in which the industry is currently engaged. Practically every issue that FDA guidance is expected to address has already been handled independently by a few pioneering pharmaceutical companies. Rather than waiting for FDA's anti climatic guidelines, Pharmaguy decided to publish The Pharmaguy Social Media Timeline™ now, at a time when the industry already has set precedents in every social media application.